Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2012; 01(01): 16-24
DOI: 10.4103/2278-330X.96498
Mini Symposium on CML

Chronic myeloid leukemia: In pursuit of perfection

Vishal Jayakar
Consultant Haemato-Oncologist, Kingston and Royal Marsden Hospitals, London, UK
› Author Affiliations Source of Support: Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

The resounding success of imatinib (IM) as front line treatment in patients with chronic myeloid leukemia (CML) has certainly made a paradigm shift in the therapeutic algorithm of this disorder. The precise targeting of the BCR-ABL oncogene in CML has entitled it to be the poster child of translational medicine with a well-deserved Oscar ovation from the oncology community. Clinicians are now empowered with first-, second- and third-generation tyrosine kinases, as well as advanced molecular tools to monitor disease and characterize resistance. We have come a long way in successfully managing these patients, but there are still a significant few unmet clinical needs which need addressing and targeting to optimize clinical outcomes. This review focuses on 4 such pertinent and relevant clinical issues, which still need ironing out to fulfill our ambition of achieving ‘perfection’ in this patient cohort.

Key words

Chronic phase chronic myeloid leukemia - cure - tyrosine kinase inhibitor


Publication History

Article published online:
09 November 2020

© 2012. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Björkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjöberg J, et al. Success story of targeted therapy in chronic myeloid leukemia: A population based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514-20.
  • 2 Michael Deininger, Stephen G O'Brien, François Guilhot, John M Goldman, Andreas Hochhaus, Timothy P. Hughes et al. IRIS 8-year follow up: Sustained survival and low risk for progression of events in patients with newly diagnosed CML treated with imatinib. Blood 2009;114:abstract 1126.
  • 3 de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with CML: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-63.
  • 4 Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, et al. A population study of imatinib in CML demonstrates lower efficacy than in clinical trials. Leukemia 2008;22:1963-6.
  • 5 Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, et al. Phase 3 randomized open-label study of daily imatinib 400 mg versus 800 mg in patients with newly diagnosed, previously untreated CML in chronic phase using molecular end points: Tyrosine kinase inhibition optimisation and selectivity study. J Clin Oncol 2010;28:424-30.
  • 6 Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed CML. J Clin Oncol 2011;29:1634-42.
  • 7 Jorge E. Cortes, Michele Baccarani, François Guilhot, Brian J. Druker, Susan Branford, Dong-Wook Kim. Phase III, Randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. JCO 2010: 28;424-30.
  • 8 Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of response to imatinib in CML. Clin Pharmacol Ther 2008;83:258-64.
  • 9 Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, et al. Imatinib plus peginterferon alfa-2a in CML. N Engl J Med 2010;363:2511-21.
  • 10 Jorge E. Cortes, Dan Jones, Susan O’Brien, Elias Jabbour, Farhad Ravandi, Charles Kolle et al. Results of dasatinib therapy in patients with early chronic phase CML. J Clin Oncol 2010;28:398- 404.
  • 11 Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, et al. Nilotinib as front-line treatment for patients with CML in early chronic phase. J Clin Oncol 2010;28:392-7.
  • 12 Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus Imatinib for newly diagnosed CML. N Engl J Med 2010;362:2251-9.
  • 13 Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus Imatinib in newly diagnosed chronic phase CML. N Engl J Med 2010;362:2260-70.
  • 14 Gambacorti-Passerini C, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L. An ongoing phase 3 study of Bosutinib versus Imatinib in patients with newly diagnosed chronic phase CML. Blood 2010;116:208.
  • 15 Joseph M. Gozgit, Matthew J. Wong, Lauren Moran, Scott Wardwell, Qurish K. Mohemmad, Narayana I. Narasimhan et al. Ponatinib (AP24534), a multitargeted Pan-FGFR inhibitor with activity in multiple FGFR-Amplified or mutated cancer models. Mol cancer ther; 2012: 11; 690–9.
  • 16 Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. CML: An update of concepts and management recommendations of European Leukaemia Net. J Clin Oncol 2009;27:60941-51.
  • 17 Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, et al. Long term prognostic significance of early molecular response to imatinib in newly diagnosed CML: An analysis from the IRIS. Blood 2010;116:3758-65.
  • 18 Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009;23:1957-63.
  • 19 Kantarjian H, Cortes J. Imatinib resistant CML: Definitions and management. Vol. 5. EHA Education Book; 2011. p. 127-31.
  • 20 Smith CC, Shah NP. TKI therapy for CML: Approach to patients with treatment naïve or refractory chronic phase disease. Hematology Am Soc Hematol Educ Program. 2011;2011:121-7.
  • 21 Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in CML. Blood Rev 2006;20:29-41.
  • 22 Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenic and molecular response is associated with increased risk of progression among patients with CML in early chronic phase receiving higher dose or standard dose imatinib therapy. Blood 2009;113:6315-21.
  • 23 Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL transcript levels at 3 months is the only requirement for predicting outcome for patients with CML treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232-8.
  • 24 Jabbour E, Deninger M, Hochhaus A. Management of adverse events associated with TKI in the treatment of CML. Leukemia 2011;25:201-10.
  • 25 Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with CML who achieve complete cytogenic responses to imatinib. J Clin Oncol 2010;28:2381-8.
  • 26 Hochhuas A. Education session: Managing CML as a chronic disease. Hematology Am Soc Hematol Educ Program 2011;2011:128-35.
  • 27 Raditch JP. CML 2010: Where are we now and where can we go? Hematology Am Soc Hematol Educ Program 2010;2010:122-8.
  • 28 Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876- 80.
  • 29 Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, et al. Conformational control inhibition of the BCR-ABL tyrosine kinase, including the gatekeeper T315I mutant, by the switchcontrol inhibitor DCC-2036. Cancer Cell 2011;19:556-68.
  • 30 Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, et al. Impact of baseline BCR-ABL mutations in response to nilotinib in patients with CML in chronic phase. J Clin Oncol 2009;27:4204-10.
  • 31 Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, et al. Dasatinib treatment of chronic phase CML: Analysis of responses according to pre-existing BCR-ABL mutations. Blood 2009;114:4944-53.
  • 32 Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with CML who have maintained complete molecular remission for at least 2 years: The prospective multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35.
  • 33 Melo JV, Ross DM. Minimal residual disease and discontinuation of therapy in CML: Can we aim at cure? Hematology Am Soc Hematol Educ Program 2011;2011:136-42.
  • 34 Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase. Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML. Haematologica. 2007 Nov;92:1579-80.